Systemic Sclerosis Insights (9.13.2024) Save
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
- Guselkumab (Tremfy) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, based on pivotal, Phase 2b/3 QUASAR study showing 50% remission at week 44 (vs 19 PBO) for those on GUS 200 mg q 4 wk https://t.co/kvtqXFUezw
- Low Placental Transfer Rates with Risankizumab
- JAMA: RCT in 101 chronic low back pain pts showed a single nondeceptive placebo injection reduced LBP intensity for 1 month https://t.co/RI9TnvmeMJ
- UK Biobank study of 34209 pts w/ Abdominal MRIs found a dose response assoc. between visceral & subcutaneous fat and chronic MSK pain, moreso in women. Is adiposity causal or casual in the pathogenesis of chronic pain? https://t.co/w4ziJf7FQD
- Conservative Treatment of Acute Vertebral Fractures A network meta-analysis of pain outcomes in patients with acute osteoporotic vertebral compression fractures (VCFs) showed short-term success with calcitonin and NSAIDs in decreasing pain during activity, but long-term…teriparatide was superior to bisphosphonates. https://t.co/EulO6EGVxq
- French retrospective study of 181 hemodialysis pts (97 on urate Rx-90% allopurinol, 9% febuxostat). W/ ULT pts had significantly fewer agout flare (HR:0.42; CI 95: 0.25-0.71). Overall flares 35% (23% ULT vs 50% w/o ULT; p 0.0002) https://t.co/9hTgsR2Kx9
- Claims analysis of two datasets showed TNFi treatment in 1st two years after newly Dx breast cancer (n 2216) had no effect on overall survival (OS); but had signif better breast cancer survival (HR 0.28; 0.08–0.98) vs csDMARD Rx. Pts on GC worse OS (HR 2.18)… https://t.co/Kxk7Sy7ahi
- CA-125 & PET/CT screening in 1432 myositis. 125 pts had CA-125 w/in 5yrs of onset - 3.1% false-positives (fibroids, endometriosis) & 14.3% false-negatives. 139 had PET done- 5.5% false-positives (LN, lung nodules), 28.6% false-negatives (missed melanoma, breast or prostate CA)… https://t.co/16KSDmp9Kz
- Cross-sectional study 69 Systemic Sclerosis Pts: 33% w/ PPI-refractory esophagitis & 2/3 w/ EGD normal esophageal mucosa. PPI-refractory esophagitis was more commonly linked to diffuse SSc subset (43 vs 17%) and GI dysmotility (66 vs 8%; p = <0.001) https://t.co/givt90C0tE
- Increasing Incidence of Morphea
- Systematic literature review IVIG in systemic sclerosis included 12 studies, 266 pts. A favorable effect was seen for skin thickening, MSK pain, GI Sxs, Steroid use, QOL. But less effect for pulmonary Dz, PFTs (stabilized?). Studies were not of high-quality https://buff.ly/3XJ4i33
- Study of 65 myositis pts w/ PM/Scl Abs found ILD as a dominant feature, esp. if double pos. w/ myositis-specific Abs (MSAs 52%). PM/Scl+ more likely women (90 vs 68%), w/ sclerodactyly (16 vs 0%). Double ++ had more ILD (91%) & mortality (21% vs 0) https://buff.ly/47x3npG
- Consensus Guidelines on Pediatric Methotrexate Use
ADD THE FIRST COMMENT
Disclosures
The author has no conflicts of interest to disclose related to this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.